GU Cancers 2024 | Genomic differences between urachal and non-urachal bladder adenocarcinoma

Antonio Cigliola, MD, IRCCS San Raffaele Hospital, Milan, Italy, discusses findings from a study assessing genomic disparities between urachal and non-urachal bladder adenocarcinoma to identify potential therapeutic targets. Distinct genomic alterations were found, where colorectal cancer-associated mutations were more prevalent in urachal adenocarcinoma, while non-urachal adenocarcinoma exhibited mutations typical of urothelial carcinoma. Both types showed targetable mutations such as PIK3CA and ERBB2, and biomarkers for anti-PD(L)1 therapy were also infrequent. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.